New insulin candidate I004 put to the test against NovoLog in healthy volunteers
NCT ID NCT07560150
First seen May 02, 2026 · Last updated May 17, 2026 · Updated 1 time
Summary
This study compares a new rapid-acting insulin (I004) with the approved insulin NovoLog in 60 healthy volunteers. The goal is to see if the new insulin is absorbed and works the same way in the body. Participants receive a single dose of each insulin in random order, and their blood sugar is carefully controlled using a glucose clamp technique.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACODYNAMICS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amphastar Study Site
RECRUITINGChula Vista, California, 91911, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.